Tesamorelin Peptide Vial
£29.99 – £144.99
Purity: >98% (HPLC on request)
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.77
Sequence: trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn- Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-Gln- Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Tesamorelin Peptide Vial Dubai
Tesamorelin peptide vial is a GHRH (growth hormone-releasing hormone) analogue that has been proven to increase IGF-1 and growth hormone levels.
Research has suggested it could bind and stimulate human growth hormone-releasing hormone receptors with the same potency as your own natural growth hormone-releasing hormone.
Research shows that Tesamorelin decreased visceral fat tissue, reducing triglycerides, nootropic effects (better cognition), and reduced C-reactive protein, which is a marker of inflammation.
For Research Only Tesamorelin stimulates the hypophysis in your brain to start secreting GH. Clinical trials have proven that Tesamorelin decreases abdominal fat with very few side effects when compared to HGH itself.
Also, it has been proven in research studies to decrease lipodystrophy syndromes in people infected with HIV.
Studies and Trials Of Tesamorelin Dubai
In a placebo-controlled trial, Tesamorelin increases GH release and has been shown to improve several cognitive function measures in cognitively normal plus mildly impaired older people.
Also, in one study, scores on executive functions standard tests plus verbal memory were higher in participants who took Tesamorelin in a twenty-week trial.
Additionally, participants who were given Tesamorelin in the 78-person trial reported higher subjective improvement, specifically in cognition related to the placebo group.
In a current study, which was funded by the NIA (National Institute on Aging), 37 adults who have mild cognitive impairments and 41 cognitively normal adults were randomised to receive a placebo or Tesamorelin (1 milligram per day subcutaneously). Tesamorelin had a protective effect related to the placebo in cognitively impaired individuals.
At the final evaluation, the scores dipped an average of 5 points with the placebo, while the patients assigned to Tesamorelin appeared to have an average decline of just less than 1 point.
DISCLAIMER: YOU MUST BE OVER 21 YEARS AND BE A HEALTH CARE PROFESSIONAL to BUY THIS PRODUCT. All of the products are to be handled only by appropriately trained and qualified LABORATORY or RESEARCH professionals. Products ARE ONLY used in the process of medical research by responsible individuals. Direct Sarms does not encourage or promote the use of any of these products in a personal capacity (i.e. human consumption), nor are the products intended to be used as a drug, stimulant or for use in any food products.
|Dimensions||1 × 1 × 1 cm|